Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Systems biology brings hope of speeding up drug development

Almost every day brings news of an apparent breakthrough against cancer, infectious diseases, or metabolic conditions like diabetes, but these rarely translate into effective therapies or drugs, and even if they do clinical development usually takes well over a decade.

19 Nov 2008

Protein transporter in the gut could speed drug 'take up'

For poorly absorbed medications, drug makers should consider using natural homing devices to drive the drugs through the hazards of gastrointestinal acidity and enzymes to reach the bloodstream quicker, James Polli, PhD, said today at the annual meeting of the American Association of Pharmaceutical Scientists (AAPS) in Atlanta.

18 Nov 2008

Accera to launch Axona, medical food product for Alzheimer's in 2009

Accera, Inc. will launch Axona in the United States for Alzheimer's disease (AD) in the first quarter of 2009.

18 Nov 2008

First simulation of the the ageing process

The first simulation of how it feels to age decades in minutes will be run by staff from Eisai at the new University of Hertfordshire simulation centre tomorrow (19 November).

18 Nov 2008

Fitch Ratings revises Merck & Co.'s outlook

Fitch Ratings has affirmed Merck & Co.'s (Merck) ratings, and revised the Rating Outlook to Negative from Stable.

18 Nov 2008

Simple, inexpensive method for detecting contaminants in heparin

The blood-thinning drug heparin is highly effective when used to prevent and treat blood clots in veins, arteries and lungs, but earlier this year its reputation as a lifesaver was sullied when contaminated heparin products caused serious allergic reactions that led to a large number of deaths.

17 Nov 2008

Women experience more harassment in work groups with male-female balance

Despite common assumptions, new research suggests that women are not more likely to be sexually harassed when they are the minority or majority in a work group.

12 Nov 2008

Santaris Pharma releases positive data on LNA-based survivin inhibitor

Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.

10 Nov 2008

Arteriocyte awarded DARPA funding for company's blood pharming technology

Arteriocyte announced today a $1,950,000 award from DARPA for the company's Nanofiber Based System (NANEX) technology for the Production of Red Blood Cells project.

10 Nov 2008

SALVAT submits complete response to FDA approvable letter for CETRAXAL

SALVAT announced today the submission of the response to the FDA Approvable Letter for CETRAXAL (Ciprofloxacin 0.2% Otic Solution in Single Dose Containers).

6 Nov 2008

BioLife Solutions submits FDA master file on HypoThermosol preservation and storage media for cells, tissues

BioLife Solutions Inc. has announced that it has submitted a Master File to the United States Food and Drug Administration (FDA) for the Company's HypoThermosol preservation media product.

6 Nov 2008

SurModics acquires drug delivery assets of PR Pharmaceuticals

SurModics, Inc. announced today that it has acquired a portfolio of intellectual property and collaborative drug delivery projects from PR Pharmaceuticals, Inc., a drug delivery company specializing in injectable, biodegradable sustained release formulations.

4 Nov 2008

Pulsed ultrasound used to remote control brain circuits

In a twist on nontraditional uses of ultrasound, a group of neuroscientists at Arizona State University has developed pulsed ultrasound techniques that can remotely stimulate brain circuit activity.

29 Oct 2008

FDA grants tentative approval for 75th generic anti-retroviral drug

The Food and Drug Administration within the U.S. Department of Health and Human Services (HHS) has reached the milestone of the 75th anti-retroviral generic drug approved or tentatively approved as part of President Bush's Emergency Plan for AIDS Relief (PEPFAR).

29 Oct 2008

HSE launch campaign on asbestos awareness - 20 tradesmen die per week

Figures issued by the Health and Safety Executive revealed that every week 20 tradesmen die from asbestos-related diseases, and this number is set to increase.

23 Oct 2008

Surface analysis exposes counterfeit medicines

CERAM Surface and Materials Analysis has published a white paper highlighting how surface analysis can expose counterfeit medicines. It describes how technologies such as X-ray photoelectron spectroscopy (XPS) and Time-of-Flight Secondary Ion Mass Spectroscopy (ToFSIMS) are being used in novel ways to not only analyse the composition of various pharmaceuticals, but also to determine differences in the manufacturing processes involved.

15 Oct 2008

GE announces battery-free RFID sensor

GE Global Research has announced a battery-free, multi-detection radio-frequency identification (RFID) sensing platform that could enable a wide range of low cost wireless sensing products in healthcare, security, food packaging, water treatment and pollution prevention. GE's unique RFID sensors are built on traditional RFID tags.

14 Oct 2008

FDA licenses for marketing Cinryze for hereditary angioedema

The U.S. Food and Drug Administration today licensed for marketing the first product in the United States intended to protect people with hereditary angioedema (HAE), a rare and potentially life-threatening genetic disease. HAE affects about 6,000 to 10,000 individuals in the United States.

12 Oct 2008

Lilly to acquire ImClone Systems for $6.5 billion

Eli Lilly and Company and ImClone Systems Inc. today announced that the boards of directors of both companies have approved a definitive merger agreement under which Lilly will acquire ImClone through an all cash tender offer of $70.00 per share, or approximately $6.5 billion.

6 Oct 2008

Advanced Life Sciences submits NDA for cethromycin in mild-to-moderate community acquired pneumonia

Advanced Life Sciences Holdings, Inc. has announced the submission of a new drug application (NDA) for cethromycin in mild-to-moderate community acquired pneumonia (CAP). Advanced Life Sciences also entered into debt and equity financing agreements to strengthen its balance sheet and help fund commitments associated with the NDA submission and pre-commercialization activities.

2 Oct 2008